CL2014003525A1 - Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. - Google Patents
Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.Info
- Publication number
- CL2014003525A1 CL2014003525A1 CL2014003525A CL2014003525A CL2014003525A1 CL 2014003525 A1 CL2014003525 A1 CL 2014003525A1 CL 2014003525 A CL2014003525 A CL 2014003525A CL 2014003525 A CL2014003525 A CL 2014003525A CL 2014003525 A1 CL2014003525 A1 CL 2014003525A1
- Authority
- CL
- Chile
- Prior art keywords
- fimasartan
- hydrochlorothiazide
- hypertension
- binder
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20120070359A KR101414873B1 (ko) | 2012-06-28 | 2012-06-28 | 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014003525A1 true CL2014003525A1 (es) | 2015-04-10 |
Family
ID=49783403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014003525A CL2014003525A1 (es) | 2012-06-28 | 2014-12-24 | Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension. |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9457094B2 (OSRAM) |
| EP (1) | EP2868316B1 (OSRAM) |
| JP (1) | JP6145506B2 (OSRAM) |
| KR (1) | KR101414873B1 (OSRAM) |
| CN (2) | CN104602676A (OSRAM) |
| AU (1) | AU2013281582B2 (OSRAM) |
| BR (1) | BR112014032764B1 (OSRAM) |
| CA (1) | CA2877444C (OSRAM) |
| CL (1) | CL2014003525A1 (OSRAM) |
| CO (1) | CO7240413A2 (OSRAM) |
| ES (1) | ES2654207T3 (OSRAM) |
| IN (1) | IN2015DN00645A (OSRAM) |
| MX (1) | MX351521B (OSRAM) |
| MY (1) | MY165075A (OSRAM) |
| PE (1) | PE20150607A1 (OSRAM) |
| PH (1) | PH12014502876A1 (OSRAM) |
| RU (1) | RU2613900C2 (OSRAM) |
| SG (1) | SG11201408666SA (OSRAM) |
| UA (1) | UA111434C2 (OSRAM) |
| WO (1) | WO2014003305A1 (OSRAM) |
| ZA (1) | ZA201409508B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105395552A (zh) * | 2014-09-05 | 2016-03-16 | 南京华威医药科技开发有限公司 | 一种含非马沙坦及其盐的固体制剂 |
| KR101545268B1 (ko) * | 2015-02-05 | 2015-08-20 | 보령제약 주식회사 | 정제 및 이의 제조방법 |
| WO2017091041A1 (ko) * | 2015-11-26 | 2017-06-01 | 보령제약 주식회사 | 피마살탄의 신규 염 |
| MX387327B (es) * | 2016-01-27 | 2025-03-18 | Boryung Pharm | Composición farmacéutica para prevenir o tratar nefropatía diabética |
| KR102233673B1 (ko) * | 2016-01-27 | 2021-03-30 | 보령제약 주식회사 | 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물 |
| CN105784867B (zh) * | 2016-03-28 | 2019-01-01 | 北京睿创康泰医药研究院有限公司 | 用于分析非马沙坦有关物质的hplc方法及这些杂质作参比标准的用途 |
| KR102201396B1 (ko) * | 2017-11-30 | 2021-01-11 | 보령제약 주식회사 | 피마살탄을 포함하는 약학적 조성물 |
| KR20220162456A (ko) * | 2021-06-01 | 2022-12-08 | 주식회사 보령 | 고혈압을 동반한 당뇨병성 신장질환의 예방 또는 치료용 약학적 조성물 |
| CN120037195B (zh) * | 2023-09-28 | 2025-11-28 | 浙江百代医药科技有限公司 | 一种硫辛酸药物组合物及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4107831B2 (ja) * | 2000-11-21 | 2008-06-25 | 第一三共株式会社 | 医薬組成物 |
| HRP20040649B1 (en) * | 2002-01-16 | 2012-12-31 | Boehringer Ingelheim Pharma | Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
| KR100678421B1 (ko) * | 2005-02-11 | 2007-02-02 | 주식회사 씨티씨바이오 | 염산 탐스로신 함유 방출조절 제제 |
| ES2523729T3 (es) | 2006-06-16 | 2014-12-01 | Lek Pharmaceuticals D.D. | Composición farmacéutica que comprende hidroclorotiazida y telmisartán |
| WO2009058950A2 (en) | 2007-10-30 | 2009-05-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
| ES2364011B1 (es) * | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares. |
| KR101058284B1 (ko) | 2010-01-22 | 2011-08-22 | 보령제약 주식회사 | 2-(2-ｎ-부틸-4-히드록시-6-메틸-피리미딘-5-일)-Ｎ,Ｎ-디메틸아세트아미드의 신규한 제조방법 |
| TR201004754A1 (tr) * | 2010-06-11 | 2012-01-23 | Sanovel �La� San. Ve T�C. A.�. | Yeni Farmasötik Kombinasyonlar |
| CN102397278A (zh) * | 2010-09-19 | 2012-04-04 | 鲁南制药集团股份有限公司 | 一种抗高血压药物组合物 |
| CN102485228B (zh) * | 2010-12-02 | 2015-06-10 | 鲁南制药集团股份有限公司 | 一种药物组合物及其用途 |
| CN102485227B (zh) * | 2010-12-02 | 2015-06-10 | 鲁南制药集团股份有限公司 | 一种药物组合物及其用途 |
| CN102058602B (zh) * | 2010-12-21 | 2013-04-10 | 中国药科大学 | 一种稳定的含氯沙坦钾和氢氯噻嗪的口服固体制剂 |
-
2012
- 2012-06-28 KR KR20120070359A patent/KR101414873B1/ko active Active
-
2013
- 2013-04-30 WO PCT/KR2013/003734 patent/WO2014003305A1/ko not_active Ceased
- 2013-04-30 JP JP2015519998A patent/JP6145506B2/ja not_active Expired - Fee Related
- 2013-04-30 MX MX2014015841A patent/MX351521B/es active IP Right Grant
- 2013-04-30 CA CA2877444A patent/CA2877444C/en active Active
- 2013-04-30 AU AU2013281582A patent/AU2013281582B2/en not_active Ceased
- 2013-04-30 ES ES13809531.0T patent/ES2654207T3/es active Active
- 2013-04-30 US US14/411,871 patent/US9457094B2/en active Active
- 2013-04-30 EP EP13809531.0A patent/EP2868316B1/en not_active Not-in-force
- 2013-04-30 PE PE2014002474A patent/PE20150607A1/es active IP Right Grant
- 2013-04-30 CN CN201380040573.0A patent/CN104602676A/zh active Pending
- 2013-04-30 MY MYPI2014003524A patent/MY165075A/en unknown
- 2013-04-30 SG SG11201408666SA patent/SG11201408666SA/en unknown
- 2013-04-30 UA UAA201500674A patent/UA111434C2/uk unknown
- 2013-04-30 RU RU2015102553A patent/RU2613900C2/ru active
- 2013-04-30 BR BR112014032764-5A patent/BR112014032764B1/pt active IP Right Grant
- 2013-04-30 IN IN645DEN2015 patent/IN2015DN00645A/en unknown
- 2013-04-30 CN CN201910766865.1A patent/CN110496122A/zh active Pending
-
2014
- 2014-12-23 ZA ZA2014/09508A patent/ZA201409508B/en unknown
- 2014-12-23 PH PH12014502876A patent/PH12014502876A1/en unknown
- 2014-12-24 CL CL2014003525A patent/CL2014003525A1/es unknown
- 2014-12-26 CO CO14284187A patent/CO7240413A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112014032764B1 (pt) | 2021-12-07 |
| US9457094B2 (en) | 2016-10-04 |
| US20150147394A1 (en) | 2015-05-28 |
| RU2613900C2 (ru) | 2017-03-21 |
| IN2015DN00645A (OSRAM) | 2015-06-26 |
| UA111434C2 (uk) | 2016-04-25 |
| MX2014015841A (es) | 2015-07-17 |
| CN110496122A (zh) | 2019-11-26 |
| JP2015525745A (ja) | 2015-09-07 |
| KR101414873B1 (ko) | 2014-07-03 |
| CA2877444A1 (en) | 2014-01-03 |
| CA2877444C (en) | 2017-08-01 |
| KR20140006233A (ko) | 2014-01-16 |
| PH12014502876B1 (en) | 2015-02-23 |
| ES2654207T3 (es) | 2018-02-12 |
| MY165075A (en) | 2018-02-28 |
| EP2868316A4 (en) | 2016-02-17 |
| SG11201408666SA (en) | 2015-03-30 |
| PE20150607A1 (es) | 2015-05-16 |
| PH12014502876A1 (en) | 2015-02-23 |
| JP6145506B2 (ja) | 2017-06-14 |
| BR112014032764A2 (pt) | 2017-06-27 |
| CN104602676A (zh) | 2015-05-06 |
| RU2015102553A (ru) | 2016-08-20 |
| CO7240413A2 (es) | 2015-04-17 |
| MX351521B (es) | 2017-10-18 |
| EP2868316B1 (en) | 2017-12-06 |
| WO2014003305A1 (ko) | 2014-01-03 |
| ZA201409508B (en) | 2016-08-31 |
| AU2013281582A1 (en) | 2015-02-05 |
| AU2013281582B2 (en) | 2016-06-09 |
| EP2868316A1 (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012004335A2 (pt) | composto, composição farmacêutica, e, uso do composto. | |
| BR112014029115A2 (pt) | composto, composição farmacêutica, e, uso de um composto ou composição | |
| BR112015000420A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CL2012003643A1 (es) | Compuesto analogo del glucagon; composicion que comprende dicho compuesto; uso del compuesto para tratar y/o prevencion de obesidad, dislipidemia o hipertension. | |
| BR112014031262A2 (pt) | composições biocatalisadoras inovadoras e processos para uso. | |
| BR112013011448A2 (pt) | composto, composição farnmacêutica, e, uso do composto | |
| BR112012031226A2 (pt) | composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica | |
| CR20150380A (es) | Compuestos de carbamoilpiridona policíclicos y su uso farmacéutico | |
| BR112014001255A2 (pt) | composto, uso de um composto, combinação, e, composição farmacêutica | |
| AR125920A2 (es) | Composiciones que comprenden vortioxetina y donepezil | |
| BR112015002541A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente. | |
| BR112013008259A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| BR112013015397A2 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CL2015000345A1 (es) | Uso de una combinación para el melanoma que comprende la administración de cobimetinib y vemurafenib. | |
| IT1403847B1 (it) | Composizioni farmaceutiche comprendenti rifaximina e loro uso. | |
| BR112015003259A2 (pt) | composto, composição farmacêutica, e, composição de vacina. | |
| CL2014000849A1 (es) | Compuestos derivados de benzilindazoles sustituido, inhibidores de la quinasa bub1; procedimiento de fabricacion; composicion farmaceutica; combinacion farmaceutica; y su uso en el tratamiento de enfermedades hiperproliferativas. | |
| BR112015002824A2 (pt) | composto, uso de um composto, composição farmacêutica, e, produto farmacêutico de combinação. | |
| CL2015001202A1 (es) | Compuestos derivados de oxazolidin-2-ona-pirimidina; composicion y combinacion farmaceutica y uso en el tratamiento del cancer. | |
| BR112014029642A2 (pt) | composto, combinação de um composto, composição farmacêutica, uso de um composto, dispositivo e kit | |
| BR112014020992A2 (pt) | Composto,uso de composto na fabricação de um medicamento e composição farmacêutica | |
| CL2012003322A1 (es) | Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer. | |
| CL2014001861A1 (es) | Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia. | |
| BR112014026873A2 (pt) | método cosmético, composição cosmética e uso. | |
| BRPI0915527A2 (pt) | pepitídeos, composição farmacêutica e exossomos compreendendo os mesmos, métodos e usos |